The influence of environmental temperature on the response of the skin to local pressure: the impact of aging and diabetes.

abstract：:Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

journal_title：Diabetes technology & therapeutics

authors： Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

更新日期：2012-11-01 00:00:00

abstract：:Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes. However, the progressive nature of the disease means that some individuals may require additional ways to maintain their glycemic goals. Intensification in these circumstances ha...

journal_title：Diabetes technology & therapeutics

authors： Perfetti R

更新日期：2011-09-01 00:00:00

abstract：:The Exubera system (Pfizer, New York, NY/Nektar Therapeutics, San Carlos, CA) is an integration of five major new technologies: protein formulation, powder processing, powder filling, drug packaging, and delivery device. The product provides a simple interface, where the patient interacts only with the delivery device...

journal_title：Diabetes technology & therapeutics

authors： Harper NJ,Gray S,De Groot J,Parker JM,Sadrzadeh N,Schuler C,Schumacher JD,Seshadri S,Smith AE,Steeno GS,Stevenson CL,Taniere R,Wang M,Bennett DB

更新日期：2007-06-01 00:00:00

abstract：:Continuous glucose monitoring (CGM) systems have been available for more than 15 years by now. However, market uptake is relatively low in most countries; in other words, relatively few patients with diabetes use CGM systems regularly. One major reason for the reluctance of patients to use CGM systems is the costs ass...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,DeVries JH

更新日期：2016-02-01 00:00:00

abstract：:This study was designed to assess the frequency of the dawn phenomenon in patients with type 2 diabetes. A secondary aim was to examine the influence of varying treatment regimens on the frequency of the dawn phenomenon. The dawn phenomenon was defined as a rise in plasma glucose levels of > or = 0.5 mmol/L (10 mg/dL)...

journal_title：Diabetes technology & therapeutics

authors： Carroll MF,Hardy KJ,Burge MR,Schade DS

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Insulin pumps (for continuous subcutaneous insulin infusion [CSII]) are used widely in type 1 diabetes mellitus. Although there has been considerable study of outcomes, there are few recent data on CSII-associated adverse events and no data on family perceptions of adverse events and their confidence in deal...

journal_title：Diabetes technology & therapeutics

authors： Wheeler BJ,Donaghue KC,Heels K,Ambler GR

更新日期：2014-04-01 00:00:00

abstract：: Background: International consensus on the use of continuous glucose monitoring (CGM) recommends coefficient of variation (CV) as the metric of choice to express glycemic variability (GV) with a cutoff of 36% to define unstable diabetes. Even though, CV is associated with ...

journal_title：Diabetes technology & therapeutics

authors： Gómez AM,Henao DC,Imitola Madero A,Taboada LB,Cruz V,Robledo Gómez MA,Rondón M,Muñoz-Velandia O,García-Jaramillo M,León Vargas FM

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Glucose variability has been identified as a predictor of hypoglycemia and has been associated with mortality in critically ill patients without diabetes. A popular metric to quantify glucose variability is the mean amplitude of glycemic excursions (MAGE). The "ruler and pencil" approach to calculate MAGE is...

journal_title：Diabetes technology & therapeutics

authors： Sechterberger MK,Luijf YM,Devries JH

更新日期：2014-02-01 00:00:00

abstract：OBJECTIVE:Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and diabetes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load (2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preoperative ...

journal_title：Diabetes technology & therapeutics

authors： Gianchandani RY,Saberi S,Zrull CA,Patil PV,Jha L,Kling-Colson SC,Gandia KG,DuBois EC,Plunkett CD,Bodnar TW,Pop-Busui R

更新日期：2011-12-01 00:00:00

abstract：:Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

journal_title：Diabetes technology & therapeutics

authors： Levine BJ,Close KL,Gabbay RA

更新日期：2020-01-01 00:00:00

abstract：: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

journal_title：Diabetes technology & therapeutics

authors： Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Stress-induced hyperglycemia is prevalent in critical care, even in patients with no history of diabetes. Increased counter-regulatory hormone response increases gluconeogenesis and effective insulin resistance, which can be exacerbated by drug therapy. Control of blood glucose levels to the 4.0-6.1 mmol/L r...

journal_title：Diabetes technology & therapeutics

authors： Lonergan T,Compte AL,Willacy M,Chase JG,Shaw GM,Hann CE,Lotz T,Lin J,Wong XW

更新日期：2006-08-01 00:00:00

abstract：:Disease registries are a searchable list of all patients with a particular chronic condition that often interface with an electronic medical record. The well-designed registry links all members of the patient's health team and provides key information for patients and physicians. The critical impact of a registry is t...

journal_title：Diabetes technology & therapeutics

authors： Khan L,Mincemoyer S,Gabbay RA

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) has been shown to improve glycemic control and reduce hypoglycemia with consistent use. Youth, however, are unlikely to use CGM consistently. We compared psychological characteristics of youth with type 1 diabetes, their parents, and adults with type 1 diabetes randomized ...

journal_title：Diabetes technology & therapeutics

authors： Markowitz JT,Pratt K,Aggarwal J,Volkening LK,Laffel LM

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

journal_title：Diabetes technology & therapeutics

authors： Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

更新日期：2018-09-01 00:00:00

abstract：OBJECTIVE:this study assessed patient-related factors associated with persistence and resumption of using pens as insulin delivery devices. METHODS:patients (n = 549; 300 current pen users, 249 former pen users) were recruited from national panels to participate in computer-assisted telephone interviews. Measures incl...

journal_title：Diabetes technology & therapeutics

authors： Peyrot M,Rubin RR

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:This study assessed the accuracy and reliability of three continuous glucose monitoring (CGM) systems. RESEARCH DESIGN AND METHODS:We studied the Animas® (West Chester, PA) Vibe™ with Dexcom® (San Diego, CA) G4™ version A sensor (G4A), the Abbott Diabetes Care (Alameda, CA) Freestyle® Navigator I (NAV), and ...

journal_title：Diabetes technology & therapeutics

authors： Luijf YM,Mader JK,Doll W,Pieber T,Farret A,Place J,Renard E,Bruttomesso D,Filippi A,Avogaro A,Arnolds S,Benesch C,Heinemann L,DeVries JH,AP@home consortium.

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) has been shown to be a valuable tool to improve glycemic control in patients with diabetes. The objective of this pilot study was to develop and implement CGM in an existing diabetes clinic for low-income patients on multiple daily injections. SUBJECTS AND METHODS:This wa...

journal_title：Diabetes technology & therapeutics

authors： Sequeira PA,Montoya L,Ruelas V,Xing D,Chen V,Beck R,Peters AL

更新日期：2013-10-01 00:00:00

abstract：:Skin integrity and diabetes device placement are ongoing concerns for people with diabetes who utilize continuous glucose monitors (CGMs) and continuous subcutaneous insulin infusion pumps. This is especially significant for individuals with skin sensitivities, pediatric patients, and those who use devices chronically...

journal_title：Diabetes technology & therapeutics

authors： Messer LH,Berget C,Beatson C,Polsky S,Forlenza GP

更新日期：2018-06-01 00:00:00

abstract：:Laser retinal photocoagulation represents the primary therapy for the potentially blinding manifestations of diabetic retinopathy. Advances in laser therapy for diabetic eye disease have arisen from the convergence of laser technology and clinical ophthalmology. In this review, the basis of laser therapy in diabetic r...

journal_title：Diabetes technology & therapeutics

authors： Petrovic V,Bhisitkul RB

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND:Computer decision support systems are potentially effective methods for adjusting insulin, but current models do not take into account simultaneous changes of more than one agent. We describe the development of the Multiagent Intelligent Dosing System (MAIDS, Dimensional Dosing Systems, Wexford, PA) for pred...

journal_title：Diabetes technology & therapeutics

authors： Cook CB,McMichael JP,Dunbar VG,Lieberman R

更新日期：2005-12-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS:This was a retrospective observational cohort study including patients for whom the protocol was order...

journal_title：Diabetes technology & therapeutics

authors： Passarelli AJ,Gibbs H,Rowden AM,Efird L,Zink E,Mathioudakis N

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:We evaluated the impact of a 2-year chat line involving adolescents with type 1 diabetes regarding quality of life and metabolic control. METHODS:We enrolled 193 children, 10-18 years of age (mean ± SD, 13.6 ± 2.7 years), with type 1 diabetes for 1.2-6 years (3.6 ± 2.4 years), body mass index of 23.2 ± 4.1 ...

journal_title：Diabetes technology & therapeutics

authors： Iafusco D,Galderisi A,Nocerino I,Cocca A,Zuccotti G,Prisco F,Scaramuzza A

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:The aim of this investigation was to assess clinical predictors of the glycosylated hemoglobin (HbA1C) response after the addition of a thiazolidinedione (TZD) to a biguanide, a sulfonylurea, or both in subjects with type 2 diabetes. METHODS:Chart review (n = 68 physicians) was used to identify consecutive ...

journal_title：Diabetes technology & therapeutics

authors： Izumi R,Hurt J,Maki KC,Bell M,Zavras AI,McCamish M

更新日期：2007-12-01 00:00:00

abstract：:Hyperspectral imaging (HSI) has been useful in monitoring several medical conditions, which to date have generally involved local changes in skin oxygenation of isolated regions of interest such as skin flaps or small burns. Here, by contrast, we present a study in which HSI was used to assess the local cutaneous mani...

journal_title：Diabetes technology & therapeutics

authors： Gillies R,Freeman JE,Cancio LC,Brand D,Hopmeier M,Mansfield JR

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Lipohypertrophy (LH) is a complication of insulin therapy. We assessed LH prevalence, risk factors, insulin usage, and clinical and health economic effects in China. METHODS:In four cities, 401 adult patients injecting insulin ≥1 year were surveyed for diabetes/insulin injection history and practices, pen n...

journal_title：Diabetes technology & therapeutics

authors： Ji L,Sun Z,Li Q,Qin G,Wei Z,Liu J,Chandran AB,Hirsch LJ

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS:The study enrolled patients aged ≥16 years with T2D treated primarily ...

journal_title：Diabetes technology & therapeutics

authors： Henry RR,Klein EJ,Han J,Iqbal N

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:The masked continuous glucose monitoring system (Masked-CGMS) differs from standard CGMSs in three ways: (1) there is no feedback to the user so that no immediate regimen changes can be made; (2) it can only be worn for up to 5 days; and (3) there are no alarms to warn of hyperglycemia or hypoglycemia. Since...

journal_title：Diabetes technology & therapeutics

authors： Duran-Valdez E,Burge MR,Broderick P,Shey L,Valentine V,Schrader R,Schade DS

更新日期：2014-05-01 00:00:00

abstract：:There are three main issues in non-invasive (NI) glucose measurements: namely, specificity, compartmentalization of glucose values, and calibration. There has been progress in the use of near-infrared and mid-infrared spectroscopy. Recently new glucose measurement methods have been developed, exploiting the effect of ...

journal_title：Diabetes technology & therapeutics

authors： Khalil OS

更新日期：2004-10-01 00:00:00

abstract：BACKGROUND:Weight gain often occurs when insulin therapy is initiated. The long-acting insulin analog insulin detemir has been shown to be effective and well tolerated when used in basal-bolus regimens or as an add-on to oral antidiabetic drugs (OADs) and causes less weight gain than other insulins. The aim of this exp...

journal_title：Diabetes technology & therapeutics

authors： Davies MJ,Derezinski T,Pedersen CB,Clauson P

更新日期：2008-08-01 00:00:00